Zenas BioPharma (ZBIO) Non-Current Assets (2023 - 2026)
Zenas BioPharma (ZBIO) posted quarterly Non-Current Assets of $17.5 million for Q1 2026, up 9.77% year-over-year from $16.0 million in Q1 2025, and down 46.05% quarter-over-quarter from $32.5 million in Q4 2025.
Zenas BioPharma (ZBIO) Non-Current Assets (2023 - 2026) Analysis & Trends
Zenas BioPharma's Non-Current Assets history runs 4 years deep, the most recent figure standing at $17.5 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 9.77% year-over-year to $17.5 million; the TTM figure through Mar 2026 stood at $89.8 million (up 87.04% YoY), while the FY2025 annual figure was $32.5 million, up 131.18% from the prior year.
- Non-Current Assets for Q1 2026 stood at $17.5 million, down from $32.5 million in the prior quarter.
- The five-year high for Non-Current Assets was $32.5 million in Q4 2025, with the low at $8.4 million in Q4 2023.
- The 4-year median for Non-Current Assets is $15.2 million (2025), against an average of $17.2 million.
- The sharpest annual moves came in 2025 and 2026: Non-Current Assets soared 162.85% in 2025, then advanced 9.77% in 2026.
- Zenas BioPharma's Non-Current Assets stood at $8.4 million in 2023, then soared by 67.68% to $14.0 million in 2024, then surged by 131.18% to $32.5 million in 2025, then sank by 46.05% to $17.5 million in 2026.
- Business Quant data shows ZBIO's Non-Current Assets at $17.5 million in Q1 2026, $32.5 million in Q4 2025, and $25.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Zenas BioPharma | 1.87 Bn | 748.44 Mn | - | 47.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.90 Mn |
| Mar 31, 2026 | 17.52 Mn |
| Dec 31, 2025 | 32.47 Mn |
| Sep 30, 2025 | 25.38 Mn |
| Jun 30, 2025 | 14.48 Mn |
| Mar 31, 2025 | 15.96 Mn |
| Dec 31, 2024 | 14.05 Mn |
| Sep 30, 2024 | 9.65 Mn |
| Dec 31, 2023 | 8.38 Mn |